Much biomedical research continues to focus on a small proportion of the human genome that has already been studied intensively. The Illuminating the Druggable Genome programme, initiated as a pilot project by the US National Institutes of Health Common Fund in 2014, is now being implemented to accelerate the investigation of subsets of understudied proteins that have potential therapeutic relevance.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
214,86 € per year
only 17,91 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).
Edwards, A. M. et al. Too many roads not taken. Nature 470, 163–165 (2011).
Nguyen, D. T. et al. Collating protein information to shed light on the druggable genome. Nucleic Acids Res. 45, D995–D1002 (2017).
Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362–369 (2015).
Bruni, G. et al. Zebrafish behavioral profiling identifies multi-target antipsychotic-like compounds. Nat. Chem. Biol. 12, 559–566 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Rodgers, G., Austin, C., Anderson, J. et al. Glimmers in illuminating the druggable genome. Nat Rev Drug Discov 17, 301–302 (2018). https://doi.org/10.1038/nrd.2017.252
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.252
